Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 52-Week High – Should You Buy?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $52.25 and last traded at $52.25, with a volume of 0 shares changing hands. The stock had previously closed at $52.25.

Wall Street Analyst Weigh In

RCDTF has been the subject of several research analyst reports. Barclays upgraded shares of Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research report on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

The stock has a 50-day moving average of $52.25 and a 200-day moving average of $51.94. The company has a market cap of $10.78 billion, a PE ratio of 26.13 and a beta of 0.33. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.